EGFR and non-small cell lung carcinoma: AXL or GAS6 knockdown [53], AXL degradation [75,198], treatment with an AXL blocking antibody [70], or treatment with the small molecule AXL inhibitors XL-880 [53], MP-470 [53], SGI-7079 [112], MGCD265 [199], MGCD516 [199], DS-1205b [200], or R428 [199,201] sensitized NSCLC cells to first generation EGFR TKIs (gefitinib or erlotinib) and delayed onset of resistance relative to EGFR TKI alone [200].